Dose Selection News Today

- Announced agreement to be acquired by GSK for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion and a premium of approximately 103%;... | May 12, 2023

EQS-News: Vivoryon Therapeutics N.V. / Key word(s): Conference Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat

DGAP-News: Vivoryon Therapeutics N.V. / Key word: Study results/Study Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that... | July 31, 2022

Safety data from 181 patients show no on-target toxicity and no clinical signs of ARIATherapeutic dose of 600 mg varoglutamstat given twice daily selected by the Data Safety Monitoring Board is known to

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Study results/StudyVivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O (news with additional features)31.07.2022 /...

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Study results/Study Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat

/PRNewswire/ -- Eisai Co. Ltd (Headquarters: Toyoko, CEO: Haruo Naito, "Eisai") announced today that the company will present research from its Alzheimers...

/PRNewswire/ -- BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new data for lecanemab (BAN2401), an investigational anti-amyloid...

STOCKHOLM, July 26, 2022 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new data for lecanemab (BAN2401), an investigational anti-amyloid beta (Aß)

Humanized mice provide tools for the preclinical development of drugs recognizing human-specific targets